These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15858611)

  • 21. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
    Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
    Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
    Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
    Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
    Song WK; Min YH; Kim YR; Lee SC
    Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Wu W; Bowen DA; Hanson CA; Pettinger AM; Shanafelt TD; Kay NE; Leis JF; Call TG
    Leuk Lymphoma; 2013 Mar; 54(3):476-82. PubMed ID: 22853816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
    Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).
    Galimberti S; Cervetti G; Cecconi N; Fazzi R; Pacini S; Guerrini F; Manetti C; Caracciolo F; Petrini M
    J Immunother; 2004; 27(5):389-93. PubMed ID: 15314547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Thomas DA; Cortes J; Giles FJ; Wierda WG; Koller CA; Ferrajoli A; Browning M; Lerner S; Albitar M; Keating MJ
    Cancer; 2003 Dec; 98(12):2657-63. PubMed ID: 14669286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
    Saadeh CE; Srkalovic G
    Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
    Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
    Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.